Positive CHMP opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma – BMS
Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has recommended approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the… read more.